Want to create an interactive transcript for this episode?
Podcast: Foundation Fighting Blindness
Episode: Eye on the Cure Podcast | Episode 88: Richard Small
Description: July 11, 2025. Richard Small, CEO of Neurotech, talks to host Ben Shaberman about ENCELTOβ’, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The therapy is a tiny, implantable capsule, the size of a rice grain, that delivers neurotrophic factors to preserve the patient's retinal cells and vision. The approach was previously developed to treat retinitis pigmentosa and age-related macular degeneration.